generic medicinal products in particular (30 days instead of 180 days) when the price of the reference product has already been approved or it has already been included in the public health insurance system.
eelkõige geneeriliste ravimite puhul (30 päeva jooksul 180 päeva asemel), kui võrdlustoode on juba kaetud riikliku ravikindlustussüsteemiga.